Abstract
carriers were explanted for histomorphometry. In a 2nd experiment carriers with 1 and 10 μg BMP-2 served as negative and positive controls and 3 co-absorbed carriers (1 μg BMP2 + 1 μg L51P, 1 μg BMP-2+3 μg L51P and 1 μg BMP-2+10 μg L51P) were implanted for 8 and 12 weeks and examined as above. Results: As shown in Figure 1 carriers with 1 μg BMP-2 showed signs of beginning osteogenesis and 10 μg BMP-2 lead to a strong increase of bone formation. In the co-absorbed carriers a dosedependend bone formation occurred and in the carriers with 1 μg BMP-2+10 μg L51P the amount of bone was the same as in the controls with 10 μg BMP-2. Conclusion: Inhibition of the BMP-2 antagonist Noggin by the receptor negative BMP-2 variant L51P leads to new bone formation, which is as effective as 10 μg BMP-2 alone.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call